Abstract: The present invention relates to a biodegradable and thermosensitive poly(organophosphazene) with a functional group, a preparation method thereof, and a use thereof for delivery of bioactive substances. According to the present invention, poly(organophosphazene) is a phosphagen-based polymer showing biodegradability, thermosensitivity, and sol-gel phase transition depending on temperature change, whereby when administered into a living body with bioactive substances such as drugs, the poly(organophosphazene) forms a gel-phase at body temperature to be capable of controlled release of the bioactive substances. Further, the poly(organophosphazene) has functional groups to chemically bind with bioactive substances through an ionic bond, covalent bond, or coordinate covalent bond to be capable of a sustained release of the bioactive substances due to its good binding property. Therefore, the poly(organophosphazene) is useful as a delivery material for bioactive substances.
Type:
Grant
Filed:
November 3, 2006
Date of Patent:
December 27, 2016
Assignee:
KIST
Inventors:
Soo-Chang Song, Sun-Mi Lee, Chang-Won Kim, Mi-Ran Park
Abstract: A skin cleansing composition, comprising (A) an alkyl ether carboxylic acid or a salt thereof represented by formula (1): wherein, R1 represents an alkyl group having 8 to 18 carbon atoms, n represents a number of from 0 to 20, and M represents a hydrogen atom, alkali metal, alkaline earth metal, ammonium, or organic ammonium, wherein, R1 has an average carbon number of from 10.8 to 12.8 and the average value of n is from 2.5 to 3.4, and wherein, the alkyl ether carboxylic acid or a salt thereof contains a component in which n=0 in an amount of from 9.
Abstract: Template-fixed ?-hairpin peptidomimetics of the general formula wherein Z is a template-fixed chain of 12 ?-amino acid residues which, depending on their positions in the chain (counted starting from the N-terminal amino acid) are Gly, or Pro, or of certain types which, as the remaining symbols in the above formula, are defined in the description and the claims, and salts thereof, have the property to selectively inhibit the growth of or to kill microorganisms such as Pseudomonas aeruginosa. They can be used as disinfectants for foodstuffs, cosmetics, medicaments or other nutrient-containing materials, or as medicaments to treat or prevent infections. These ?-hairpin peptidomimetics can be manufactured by processes which are based on a mixed solid- and solution phase synthetic strategy.
Type:
Grant
Filed:
November 7, 2013
Date of Patent:
December 20, 2016
Assignees:
POLYPHOR LTD., UNIVERSITAET ZUERICH
Inventors:
Steven J. Demarco, Wim Vrijbloed, Ricardo Dias, John Anthony Robinson, Nityakalyani Srinivas, Frank Gombert, Daniel Obrecht
Abstract: The present invention relates to new rhenium compounds of formula (I) with medical utility, corresponding pharmaceutical compositions as well as medical uses thereof.
Type:
Grant
Filed:
March 4, 2011
Date of Patent:
December 6, 2016
Assignee:
UNIVERSITY OF ZURICH
Inventors:
Fabio Zobi, Roger Alberto, Lukas Kromer
Abstract: There is provided inter alia a pharmaceutical dosage form for oral administration comprising a sanglifehrin as active ingredient in which the sanglifehrin active ingredient is protected from acid degradation in the stomach environment following oral administration.
Type:
Grant
Filed:
October 24, 2012
Date of Patent:
November 29, 2016
Assignee:
NeuroVive Pharmaceutical AB
Inventors:
Matthew Alan Gregory, Steven James Moss
Abstract: The present invention is directed to polyphenolic polymers formed from dihydroxybenzoic acid (DHB) derivatives or from resorcinol derivatives, monomers which form such polymers, blends of the polymers with drugs and/or additional polymers, as well as medical devices formed from, coated with, impregnated by or coverings made with any of the foregoing polymers (with or without drugs) or blends (with or without drugs).
Abstract: Inflammation caused by disease states such as rheumatism, gout, neurodegeneration and tumours result in the increased effectiveness of the opioid peptide biphalin or its analogues, due likely to the increased permeability of the “blood-brain barrier”, due to which it becomes possible to use the opioid peptide to produce a new analgesic for use during inflammation caused by rheumatism, gout, neurodegeneration, post-surgical or post-accidental trauma or tumours.
Type:
Grant
Filed:
March 7, 2008
Date of Patent:
November 8, 2016
Inventors:
Andrzej W. Lipkowski, Daniel Carr, Aleksandra Misicka-Kesik, Piotr Kosson, Anna Klinowiecka
Abstract: The invention relates to a cosmetic composition comprising, in a cosmetically acceptable medium, a compound that can be obtained by reaction between an OH-functionalized or COOH-functionalized wax and a junction group capable of establishing hydrogen bonds with one or more partner junction groups, said junction group comprising at least one unit of formula (I) or (II): The invention also relates to a cosmetic treatment process using said compounds.
Abstract: A medicinal preparation is desired which has no harmful side effects such as hypersensitive reaction, heightens the water solubility of a sparingly water-soluble anticancer agent, maintains a high drug concentration in the blood, accumulates a drug in a tumor tissue at a high concentration, heightens the pharmacological effect of the sparingly water-soluble anticancer agent, and diminishes the side effects of the anticancer agent.
Abstract: The present invention is directed, in part, to compounds and methods for imaging the central nervous system or cancer, comprising administering to a subject a contrast agent which comprises a compound that binds MC-I, and an imaging moiety, and scanning the subject using diagnostic imaging.
Type:
Grant
Filed:
February 27, 2009
Date of Patent:
August 9, 2016
Assignee:
Lantheus Medical Imaging, Inc.
Inventors:
Simon P. Robinson, David S. Casebier, Ming Yu, Mikhail Kagan, Joel Lazewatsky
Abstract: The present invention provides synthesis of a novel series of cationic lipopeptides with integrin-binding RGD functionalities. The invention also provides high L27 (transformed S1 80, mouse sarcoma cells) cell tropic gene transfer properties of these novel RGD-lipopeptides. Since L27 cell surface contains over expressed integrins, the present class of lipopeptides with integrin-binding RGD ligands are likely to find future applications in targeting anti-cancer genes/drugs to the endothelial cells of tumor vasculatures (possessing over expressed integrins).
Type:
Grant
Filed:
March 30, 2007
Date of Patent:
August 2, 2016
Assignee:
Council of Scientific and Industrial Research
Abstract: A process for forming lactose suitable for use in a pharmaceutical formulation comprises providing a plurality of lactose particles containing no more than 10% w/w of lactose particles having a volume average particle size of about 70 microns or less; milling the plurality of lactose particles to yield a plurality of milled lactose particles with an average particle size, (D50), ranging from about 50 microns to about 100 microns; and classifying the plurality of milled lactose particles into at least two fractions comprising a fine fraction and a coarse fraction wherein the fine fraction has an average particle size, (D50), ranging from about 3 microns to about 50 microns, and the coarse fraction has an average particle size, (D50), ranging from about 40 microns to about 250 microns.
Type:
Grant
Filed:
February 6, 2006
Date of Patent:
June 14, 2016
Assignees:
DMV-FONTERRA EXCIPIENTS TECHNOLOGY GMBH, GLAXO GROUP LIMITED
Inventors:
Stephen Newman, Rudolf Johannes Damhuis
Abstract: Provided herein are phenylboronate containing co-polymers (PCC), compositions containing PCC and polyvinyl alcohol (PVA), such compositions further including proteins, methods of making these compositions by water in oil polymerization, and methods of using the protein containing compositions for releasing proteins. Such phenylboronate containing co-polymers are of Formula I: where m, n, p, x, R1-R5, L, X1 and X2 are defined in the application.
Abstract: There is provided a dry powder pharmaceutical composition for inhalation useful for preventing and/or treating influenza virus infections contains as a medicinal component a compound represented by formula (I): and optionally a compound represented by formula (II): a pharmacologically acceptable salt thereof, or a hydrate thereof.
Abstract: Described are transdermal drug delivery systems for the transdermal administration of testosterone, comprising a polymer matrix and testosterone. Methods of making and using such systems also are described.
Abstract: Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula Ia or Ib, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.
Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
Type:
Grant
Filed:
April 14, 2010
Date of Patent:
March 8, 2016
Assignee:
ABBVIE INC.
Inventors:
Pamela L. Donner, Lissa T. Nelson, Tammie K. Jinkerson, Ryan G. Keddy, Christopher E. Motter, Mark A. Matulenko, Allan C. Krueger, David A. DeGoey, Sachin V. Patel, John T. Randolph, Warren M. Kati, Charles W. Hutchins, Todd N. Soltwedel
Abstract: A cleansing composition containing the following components (A) and (B): (A) an ether carboxylate of Formula (1) R1—O—(CH2CH2O)n—CH2—COOX (1) wherein —R1 represents a linear or branched C4-C10 alkyl or alkenyl group, —n represents a number from 0.5 to 20, and —X represents a hydrogen atom or a cation selected from the group consisting of an alkali metal, an alkaline earth metal, ammonium, an alkylammonium, an alkanolammonium, and a glucammonium; and (B) an ether carboxylate of Formula (2) R2—O—(CH2CH2O)m-CH2—COOY (2) wherein —R2 represents a linear or branched C12-C22 alkyl or alkenyl group, —m represents a number from 0.5 to 20, and —Y represents a hydrogen atom or a cation, selected from the group consisting of an alkali metal, an alkaline earth metal, ammonium, an alkylammonium, an alkanolammonium, and a glucammonium.
Abstract: The invention relates to stable pharmaceutical compositions comprising the compound of the below formula, or pharmaceutically acceptable salts, solvates, hydrates or morphological forms thereof.
Type:
Grant
Filed:
January 8, 2013
Date of Patent:
February 23, 2016
Assignee:
ACTELION PHARMACEUTICALS LTD.
Inventors:
Charles Tokunbo Adesuyi, Bruce Hamilton Lithgow, Olivier Lambert, Lovelace Holman
Abstract: There is provided a formulation suitable for transmucosal administration comprising a short acting hypnotic drug, which formulation provides a measurable plasma concentration of drug within 10 minutes of administration. The formulation is capable of providing sleep on demand, and preferably comprises particles of drug, for example zolpidem or a pharmaceutically-acceptable salt thereof and a mucoadhesion promoting agent, such as sodium carboxymethylcellulose, which particles of drug and mucoadhesive are presented upon the surface of larger carrier particles.
Type:
Grant
Filed:
October 26, 2005
Date of Patent:
February 23, 2016
Assignee:
Orexo AB
Inventors:
Anders Pettersson, Christer Nyström, Susanne Bredenberg